Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb Study to Determine the Safety and Efficacy of Candidate INfluenza Vaccine MVA-NP+M1 in Combination With Licensed InaCTivated inflUenza Vaccine in adultS Aged 65 Years and Above

Next Previous
Trial Profile

A Phase IIb Study to Determine the Safety and Efficacy of Candidate INfluenza Vaccine MVA-NP+M1 in Combination With Licensed InaCTivated inflUenza Vaccine in adultS Aged 65 Years and Above

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VTP 100 (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Therapeutic Use
  • Acronyms INVICTUS
  • Sponsors Barinthus Biotherapeutics

    • Most Recent Events

    • 17 Nov 2019 Planned number of patients changed from 2048 to 2030.
    • 20 Nov 2018 Status changed from recruiting to discontinued due to change to recommended season flu vaccine in UK
    • 19 Jan 2018 According to a Vaccitech media release, first round of participants has been recruited with over 862 people, this marks the end of the first phase of the trial, which will open again for new participants at the start of the winter flu vaccination programme in late 2018.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top